GlassScriptPhysician profile
Salim S Bhaloo
NPI 1881672285
$20,056.91
in general payments reported to CMS, 2019-2025
32 companies · $2,715 in 2025
The $2,715 reported for 2025 was more than what 93% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $727 · 2020: $391 · 2021: $5,233 · 2022: $5,978 · 2023: $3,070 · 2024: $1,943 · 2025: $2,715.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,251 · Consulting Fee: $406 · Education: $70.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,250.87 |
| Consulting Fee | $405.95 |
| Education | $70.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $5,861.77 | 2022-2025 | Propel, Stealthstation S8 Platform, Hydrodebrider |
| Stryker Corporation | $3,611.06 | 2019-2025 | Scopis Ent, Xpress Ent Dilation System, Hemopore |
| Intersect Ent, INC. | $3,582.12 | 2019-2022 | |
| Aerin Medical INC. | $2,584.99 | 2022-2025 | |
| Acclarent, INC | $661.12 | 2019-2023 | Trudi Nav Cable, Relieva Spinplus |
| Glaxosmithkline, LLC. | $596.36 | 2021-2025 | Nucala |
| Regeneron Healthcare Solutions, INC. | $569.63 | 2022-2025 | Dupixent |
| Optinose US, INC. | $475.36 | 2019-2025 | |
| Integra Lifesciences Corporation | $290.05 | 2020-2025 | Relieva Spinplus Nav, Trudi Probe, Inspira Air |
| Chitogel Limited | $281.77 | 2023 | Chitogel Endoscopic Sinus Surgery Kit |
| Inspire Medical Systems, INC. | $156.07 | 2023-2025 | Inspire |
| Astrazeneca Pharmaceuticals LP | $147.85 | 2023-2025 | Fasenra |
| Olympus America INC. | $147.63 | 2019-2023 | |
| Blueprint Medicines Corporation | $129.60 | 2022-2024 | Ayvakit |
| Baudax Bio INC. | $125.00 | 2020 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $112.38 | 2021-2023 | Hyqvia |
| Ethicon US, LLC | $86.98 | 2020 | |
| Xoran Technologies LLC | $75.00 | 2019 | |
| Smith+Nephew, INC. | $71.31 | 2020-2025 | Tula, Halo |
| Hikma Pharmaceuticals USA | $66.88 | 2024-2025 | Ryaltris |
| Ars Pharmaceuticals Operations, INC. | $63.72 | 2025 | Neffy |
| Genzyme Corporation | $60.69 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $52.99 | 2024 | |
| Amgen INC. | $37.32 | 2025 | Tezspire |
| Med-El Corporation | $35.15 | 2023 | Mi1250 Synchrony 2 Flexsoft, Bci 602 Kit |
| Merck Sharp & Dohme LLC | $32.33 | 2021-2023 | |
| Genentech USA, INC. | $32.33 | 2025 | Xolair |
| Phadia US INC. | $29.51 | 2024 | Immunocap |
| Alk-Abello, INC | $24.84 | 2024 | Standardized Mite D. Farinae, Histamine Positive, Timothy, Standardized |
| Phathom Pharmaceuticals, INC. | $22.27 | 2025 | Voquezna |
| Baxter Healthcare | $18.91 | 2021 | |
| Philips North America LLC | $13.92 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Salim Bhaloo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.